Lopid and Cyclophosphamide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lopid (gemfibrozil) and Cyclophosphamide (cyclophosphamide). Common drug interactions include dizziness among females and alanine aminotransferase increased among males.

The phase IV clinical study analyzes what interactions people have when they take Lopid and Cyclophosphamide. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Lopid?

Lopid has active ingredients of gemfibrozil. It is often used in high blood cholesterol. eHealthMe is studying from 9,700 Lopid users. Check the latest studies of Lopid.

What is Cyclophosphamide?

Cyclophosphamide has active ingredients of cyclophosphamide. It is often used in multiple myeloma. eHealthMe is studying from 185,240 Cyclophosphamide users. Check the latest studies of Cyclophosphamide.

On Jul, 10, 2026

18 people who take Lopid and Cyclophosphamide together, and have interactions are studied.

Lopid and Cyclophosphamide drug interactions.

What are the common drug interactions of Lopid and Cyclophosphamide, by gender? *:

female:

Dizziness
Dyspepsia (indigestion)
Dysphagia (a condition in which swallowing is difficult or painful)
Dysphonia (speech disorder attributable to a disorder of phonation)
Ejection fraction decreased (systolic heart failure)
Emotional distress
Escherichia sepsis (bacterial infection by escherichia coli)
Exostosis (formation of new bone on the surface of a bone)
Exposed bone in jaw
Face oedema (swelling of face)

male:

Alanine aminotransferase increased
Anaemia (lack of blood)
Dizziness
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Haemodilution (increase in the volume of plasma in relation to red blood cells)
Laboratory test abnormal
Lymphoma (cancer that begins in immune system cells)
Nausea (feeling of having an urge to vomit)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Pneumonia

What are the common drug interactions of Lopid and Cyclophosphamide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Adverse event
Angioedema (rapid swelling of the dermis)
Disease recurrence
Laboratory test abnormal
Lymphoma (cancer that begins in immune system cells)
Pneumonia
Pruritus generalised (generalized itching)
Thrombocytopenia (decrease of platelets in blood)
Urticaria (rash of round, red welts on the skin that itch intensely)

50-59:

Drug ineffective
Dyspnoea (difficult or laboured respiration)
Electrocardiogram st segment depression
Hyperhidrosis (abnormally increased sweating)
Hypokalaemia (low potassium)
Mitral valve incompetence (inefficient heart valve)
Nausea (feeling of having an urge to vomit)
Neutropenia (an abnormally low number of neutrophils)
Pain
Pco2 decreased

60+:

Anaemia (lack of blood)
Diarrhoea
Asthenia (weakness)
Back pain
Carotid artery stenosis (narrowing of carotid artery)
Chest pain
Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Dizziness
Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)

What are the existing conditions these people have? *

Interleukin Level Increased: 3 people, 16.67%
Febrile Neutropenia (fever with reduced white blood cells): 3 people, 16.67%
Diffuse Large B-Cell Lymphoma Refractory (cancer of b cells, a type of white blood cell-relapsed): 3 people, 16.67%
Breast Cancer: 3 people, 16.67%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 2 people, 11.11%
Anaplastic Large Cell Lymphoma T- And Null-Cell Types (t-cell or null-cell cancer, a type of blood cancer): 2 people, 11.11%
Poor Quality Sleep: 1 person, 5.56%
Occipital Neuralgia (a condition characterized by chronic pain in the upper neck): 1 person, 5.56%
Neoplasm Malignant (cancer tumour): 1 person, 5.56%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Lopid and Cyclophosphamide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously